查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1417482

药物基因体学技术市场报告：2030 年趋势、预测与竞争分析

Pharmacogenomics Technology Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 - page report | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

药物基因体学技术趋势与预测

预计到 2030 年，全球药物基因体学技术市场将达到 124 亿美元，2024 年至 2030 年复合年增长率为 6.7%。该市场的主要驱动力是基因组学领域在阐明遗传差异及其对药物反应性影响方面的重大进展、由于慢性病患病率增加而日益增加的个性化治疗需求、基因组序列测定成本的下降以及技术的进步。全球药物基因体学技术市场的未来看起来充满希望，肿瘤学、神经学、循环系统、免疫学和感染疾病市场都有机会。

药物基因体学技术市场洞察

Lucintel认为，由于PCR可以扩增特定的DNA序列，因此它是基因分型和确定与药物反应相关的遗传变异的重要工具，PCR是基因分型和确定与药物反应相关的遗传变异的重要工具。我们期望它在预测期内仍然是最大的部分，因为它经常用于查找 SNP。

由于该行业知名公司的存在、有利的保险报销规则、人们日益认识到早期诊断对改善治疗的重要性以及该地区发达的医疗基础设施，预计北美在预测期内将表现良好。继续保持最大地区地位。

常问问题

Q1.市场规模有多大？

A1. 到2030年，全球药物基因体学技术市场预计将达到124亿美元。

Q2.市场成长预测如何？

A2. 2024年至2030年，全球药物基因体学技术市场预计将以6.7%的复合年增长率成长。

Q3.影响市场成长的主要驱动因素有哪些？

A3. 该市场的主要驱动力是基因组学领域在了解遗传差异及其对药物反应性影响方面的重大进展、由于慢性病数量不断增加而对个性化治疗的需求不断增长，以及序列测定。这些是成本降低和技术进步。

Q4.市场的主要细分市场是什么？

A4. 全球药物基因体学技术市场前景广阔，肿瘤、神经疾病、循环系统疾病、免疫疾病、感染疾病等市场机会庞大。

Q5. 市场上主要企业有哪些？

A5. 主要药物基因体学技术公司如下。

  • GE HealthCare
  • Agilent Technologies
  • F. Hoffmann-La Roche
  • FOUNDATION MEDICINE
  • Thermo Fisher Scientific
  • Leica Biosystems Nussloch
  • Pfizer

Q6.未来最大的细分市场是什么？

A6.Lucintel认为PCR可以扩增特定的DNA序列，是基因分型和确定与药物反应相关的遗传变异的重要工具，PCR可以扩增特定的DNA序列，是基因分型和确定的重要工具与药物反应相关的遗传变异。我们预期它在预测期内仍将是最大的部分，因为它经常用于查找类型(SNP)。

Q7. 未来五年预计哪个地区将成为最大的市场？

A7. 由于该领域知名公司的存在、有利的报销规则、人们日益认识到早期诊断以改善治疗的重要性以及该领域发达的医疗基础设施，预计北美市场将是一个疲软的市场。预计在此期间仍将是最大的地区。

Q8. 可以客製化报告吗？

A8. 是的，Lucintel 提供 10% 的客製化服务，无需额外付费。

目录

第一章执行摘要

第二章全球药物基因体学技术市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球药物基因体学技术市场趋势（2018-2023）与预测（2024-2030）
  • 按技术分類的全球药物基因体学技术市场
    • PCR
    • 原位杂合反应
    • 免疫组织化学
    • 顺序
    • 其他的
  • 按治疗领域分類的全球药物基因体学技术市场
    • 瘤
    • 神经系统疾病
    • 循环系统疾病
    • 免疫疾病
    • 感染疾病
    • 其他的

第四章 2018-2030年区域市场趋势及预测分析

  • 全球药物基因体学技术市场区域分布
  • 北美药物基因体学技术市场
  • 欧洲药物基因体学技术市场
  • 亚太药物药物基因体学技术市场
  • 其他地区药物基因体学技术市场

第五章 竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
    • 全球药物基因体学技术市场成长机会（按技术）
    • 全球药物基因体学技术市场成长机会（按治疗领域）
    • 全球药物基因体学技术市场成长机会（按地区）
  • 全球药物基因体学技术市场的新趋势
  • 战略分析
    • 新产品开发
    • 全球药物基因体学技术市场的产能扩张
    • 全球药物基因体学技术市场的合併、收购与合资
    • 认证和许可

第七章主要企业概况

  • GE HealthCare
  • Agilent Technologies
  • F. Hoffmann-La Roche
  • FOUNDATION MEDICINE
  • Thermo Fisher Scientific
  • Leica Biosystems Nussloch
  • Pfizer
简介目录

Pharmacogenomics Technology Trends and Forecast

The future of the global pharmacogenomics technology market looks promising with opportunities in the oncology, neurological disorder, cardiovascular disease, immunological disorder, and infectious diseases market. The global pharmacogenomics technology market is expected to reach an estimated $12.4 billion by 2030 with a CAGR of 6.7% from 2024 to 2030. The major drivers for this market are significant progress in comprehending genetic differences in the field of genomics and their influence on medication responsiveness, growing need for individualized treatment owing to the increasing incidence of chronic illnesses, and the decrease in cost of genome sequencing and advances in technology.

A more than 150-page report is developed to help in your business decisions.

Pharmacogenomics Technology by Segment

The study includes a forecast for the global pharmacogenomics technology by technology, therapeutic area, and region.

Pharmacogenomics Technology Market by Technology [Shipment Analysis by Value from 2018 to 2030]:

  • PCR
  • In-Situ Hybridization
  • Immunohistochemistry
  • Sequencing
  • Others

Pharmacogenomics Technology Market by Therapeutic Area [Shipment Analysis by Value from 2018 to 2030]:

  • Oncology
  • Neurological Disorders
  • Cardiovascular Disease
  • Immunological Disorders
  • Infectious Diseases
  • Others

Pharmacogenomics Technology Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Pharmacogenomics Technology Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies pharmacogenomics technology companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the pharmacogenomics technology companies profiled in this report include-

  • GE HealthCare
  • Agilent Technologies
  • F. Hoffmann-La Roche
  • FOUNDATION MEDICINE
  • Thermo Fisher Scientific
  • Leica Biosystems Nussloch
  • Pfizer

Pharmacogenomics Technology Market Insights

Lucintel forecasts that PCR will remain the largest segment over the forecast period because it enables the amplification of particular DNA sequences, which makes it an essential tool for genotyping and determining genetic variants linked to medication response, and it is frequently used to find genetic alterations and single nucleotide polymorphisms (SNPs) that impact drug efficacy and metabolism.

North America will remain the largest region over the forecast period due to existence of prominent companies in this area, advantageous reimbursement rules, rise in awareness of the importance of early diagnosis for improved treatment, and a well-developed healthcare infrastructure in this area.

Features of the Global Pharmacogenomics Technology Market

Market Size Estimates: Pharmacogenomics technology market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Pharmacogenomics technology market size by technology, therapeutic area, and region in terms of value ($B).

Regional Analysis: Pharmacogenomics technology market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different technology, therapeutic area, and regions for the pharmacogenomics technology market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the pharmacogenomics technology market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the pharmacogenomics technology market size?

Answer: The global pharmacogenomics technology market is expected to reach an estimated $12.4 billion by 2030.

Q2. What is the growth forecast for pharmacogenomics technology market?

Answer: The global pharmacogenomics technology market is expected to grow with a CAGR of 6.7% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the pharmacogenomics technology market?

Answer: The major drivers for this market are significant progress in comprehending genetic differences in the field of genomics and their influence on medication responsiveness, growing need for individualized treatment owing to the increasing incidence of chronic illnesses, and the decrease in cost of genome sequencing and advances in technology.

Q4. What are the major segments for pharmacogenomics technology market?

Answer: The future of the global pharmacogenomics technology market looks promising with opportunities in the oncology, neurological disorder, cardiovascular disease, immunological disorder, and infectious diseases market.

Q5. Who are the key pharmacogenomics technology market companies?

Answer: Some of the key pharmacogenomics technology companies are as follows.

  • GE HealthCare
  • Agilent Technologies
  • F. Hoffmann-La Roche
  • FOUNDATION MEDICINE
  • Thermo Fisher Scientific
  • Leica Biosystems Nussloch
  • Pfizer

Q6. Which pharmacogenomics technology market segment will be the largest in future?

Answer: Lucintel forecasts that PCR will remain the largest segment over the forecast period because it enables the amplification of particular DNA sequences, which makes it an essential tool for genotyping and determining genetic variants linked to medication response, and it is frequently used to find genetic alterations and single nucleotide polymorphisms (SNPs) that impact drug efficacy and metabolism.

Q7. In pharmacogenomics technology market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to existence of prominent companies in this area, advantageous reimbursement rules, rise in awareness of the importance of early diagnosis for improved treatment, and a well-developed healthcare infrastructure in this area.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the pharmacogenomics technology market by technology (PCR, in-situ hybridization, immunohistochemistry, sequencing, and others), therapeutic area (oncology, neurological disorders, cardiovascular disease, immunological disorders, infectious diseases, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Pharmacogenomics Technology Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Pharmacogenomics Technology Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Pharmacogenomics Technology Market by Technology
    • 3.3.1: PCR
    • 3.3.2: In-situ Hybridization
    • 3.3.3: Immunohistochemistry
    • 3.3.4: Sequencing
    • 3.3.5: Others
  • 3.4: Global Pharmacogenomics Technology Market by Therapeutic Area
    • 3.4.1: Oncology
    • 3.4.2: Neurological Disorders
    • 3.4.3: Cardiovascular Disease
    • 3.4.4: Immunological Disorders
    • 3.4.5: Infectious Diseases
    • 3.4.6: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Pharmacogenomics Technology Market by Region
  • 4.2: North American Pharmacogenomics Technology Market
    • 4.2.2: North American Pharmacogenomics Technology Market by Therapeutic Area: Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders, Infectious Diseases, and Others
  • 4.3: European Pharmacogenomics Technology Market
    • 4.3.1: European Pharmacogenomics Technology Market by Technology: PCR, In-situ Hybridization, Immunohistochemistry, Sequencing, and Others
    • 4.3.2: European Pharmacogenomics Technology Market by Therapeutic Area: Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders, Infectious Diseases, and Others
  • 4.4: APAC Pharmacogenomics Technology Market
    • 4.4.1: APAC Pharmacogenomics Technology Market by Technology: PCR, In-situ Hybridization, Immunohistochemistry, Sequencing, and Others
    • 4.4.2: APAC Pharmacogenomics Technology Market by Therapeutic Area: Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders, Infectious Diseases, and Others
  • 4.5: ROW Pharmacogenomics Technology Market
    • 4.5.1: ROW Pharmacogenomics Technology Market by Technology: PCR, In-situ Hybridization, Immunohistochemistry, Sequencing, and Others
    • 4.5.2: ROW Pharmacogenomics Technology Market by Therapeutic Area: Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders, Infectious Diseases, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Pharmacogenomics Technology Market by Technology
    • 6.1.2: Growth Opportunities for the Global Pharmacogenomics Technology Market by Therapeutic Area
    • 6.1.4: Growth Opportunities for the Global Pharmacogenomics Technology Market by Region
  • 6.2: Emerging Trends in the Global Pharmacogenomics Technology Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Pharmacogenomics Technology Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Pharmacogenomics Technology Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: GE HealthCare
  • 7.2: Agilent Technologies
  • 7.3: F. Hoffmann-La Roche
  • 7.4: FOUNDATION MEDICINE
  • 7.5: Thermo Fisher Scientific
  • 7.6: Leica Biosystems Nussloch
  • 7.7: Pfizer